Please use this identifier to cite or link to this item:
Scopus Web of Science® Altmetric
Type: Journal article
Title: A randomized, comparative study of three doses of AZD0865 and esomeprazole for healing of reflux esophagitis
Author: Kahrilas, P.
Dent, J.
Lauritsen, K.
Malfertheiner, P.
Denison, H.
Franzen, S.
Hasselgren, G.
Citation: Clinical Gastroenterology and Hepatology, 2007; 5(12):1385-1391
Publisher: W. B. Saunders & Co.
Issue Date: 2007
ISSN: 1542-3565
Statement of
Peter J. Kahrilas, John Dent, Karsten Lauritsen, Peter Malfertheiner, Hans Denison, Stefan Franzén and Goran Hasselgren
Abstract: <h4>Background & aims</h4>AZD0865 belongs to a new class of acid-suppressing agents with rapid onset of action and potent acid inhibition. We evaluated its effectiveness for healing reflux esophagitis.<h4>Methods</h4>One thousand five hundred twenty-one patients with Los Angeles A-D esophagitis and heartburn of moderate or severe intensity for > or = 4 days/week were randomized to AZD0865 25, 50, or 75 mg or esomeprazole 40 mg once daily for 4-8 weeks. The primary end point was esophagitis healing by AZD0865 at 4 weeks. Healing and control of heartburn were also assessed at 2, 4, and 8 weeks for AZD0865 and esomeprazole.<h4>Results</h4>After 4 weeks of treatment, healing rates were similar among AZD0865 doses (76.9%; confidence interval [CI], 72.4%-81.1%); 78.2% (CI, 73.7%-82.3%), and 81.1% (CI, 76.7%-84.9%) for 25, 50, and 75 mg, respectively). The healing rate with esomeprazole at 4 weeks was similar (81.9%; CI, 77.6%-88.7%), and healing rates also were comparable among all treatments at 2 and 8 weeks. There were no significant differences in heartburn control among treatments. AZD0865 and esomeprazole were well-tolerated, although reversible increases in transaminases occurred in a small number of patients receiving AZD0865, especially at the 75-mg dose.<h4>Conclusions</h4>AZD0865 25, 50, and 75 mg provided similar efficacy to esomeprazole 40 mg in terms of esophagitis healing and heartburn control. These findings suggest that increasing the degree of acid inhibition beyond that already achieved by esomeprazole 40 mg (or AZD0865 25 mg) does not translate into increased clinical efficacy in esophagitis patients.
Keywords: Humans; Esophagitis, Peptic; Imidazoles; Pyridines; Enzyme Inhibitors; Gastric Acidity Determination; Treatment Outcome; Administration, Oral; Retrospective Studies; Follow-Up Studies; Double-Blind Method; Dose-Response Relationship, Drug; Hydrogen-Ion Concentration; Adolescent; Adult; Aged; Middle Aged; Patient Satisfaction; Female; Male; Esomeprazole
Rights: Copyright © 2007 AGA Institute Published by Elsevier Ltd.
RMID: 0020074113
DOI: 10.1016/j.cgh.2007.08.014
Appears in Collections:Medicine publications

Files in This Item:
There are no files associated with this item.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.